GlassScriptPhysician profile
Destin Stone Thomas
NPI 1407476336
$2,665.51
in general payments reported to CMS, 2019-2025
11 companies · $37.51 in 2025
The $37.51 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,532 · 2024: $1,096 · 2025: $37.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.02 |
| Education | $159.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $694.65 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $377.71 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $297.83 | 2023-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $267.78 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $247.03 | 2023-2024 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.67 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $188.32 | 2023-2024 | Ingrezza |
| Lundbeck LLC | $146.68 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $143.37 | 2023-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $80.55 | 2023-2024 | Fanapt, Hetlioz |
| Indivior INC. | $22.92 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Destin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.